Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of REGN6569, an Anti-GITR mAb, With Cemiplimab in Patients With Advanced Solid Tumor Malignancies
Conditions
Interventions
REGN6569
Cemiplimab
Locations
10
United States
Angeles Clinic and Research Institute - Clinic/Outpatient Facility
Los Angeles, California, United States
H.Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
University of Michigan
Ann Arbor, Michigan, United States
START South Texas Accelerated Research Therapeutics
Grand Rapids, Michigan, United States
Hospital Universitario Vall d'Hebrón
Barcelona, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
Start Date
October 5, 2020
Primary Completion Date
February 7, 2025
Completion Date
February 7, 2025
Last Updated
February 24, 2025
NCT04895709
NCT05952934
NCT06385080
NCT06487403
NCT06242470
NCT05553782
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions